AU Patent

AU2014353150A1 — Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5

Assigned to Vanderbilt University · Expires 2016-07-07 · 10y expired

What this patent protects

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with…

USPTO Abstract

Disclosed are negative allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Drugs covered by this patent

Patent Metadata

Patent number
AU2014353150A1
Jurisdiction
AU
Classification
—
Expires
2016-07-07
Drug substance claim
No
Drug product claim
No
Assignee
Vanderbilt University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.